Study study type PathologyT1T0Patientssample sizesROB Results

breast cancer - adjuvant breast cancer - adjuvant

versus placebo
everolimus
Bachelot, 2022
  NCT01805271
RCTbreast cancer - adjuvanteverolimus for 2 years combined with standard endocrine therapyplacebo for 2 years combined with standard placebowomen with high-risk, hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer-/-NA
inconclusive
    no statistically significant result

la/mBC - HR-positive - 2nd line (L2) breast cancer - HR positive la/mBC - HR positive la/mBC - HR-positive - 2nd line (L2)

versus fulvestrant
sapanisertib plus fulvestrant
NCT02756364 (sapanisertib daily), 2022
  NCT02756364
RCTla/mBC - HR-positive - 2nd line (L2)sapanasertib plus fulvestrantfulvestrantPostmenopausal women with histologic confirmation of ER-positive and HER2-negative metastatic or advanced BC47 / 46some concern
inconclusive
  • inconclusive 23 % decrease in progression or deaths (PFS) (PE)
NCT02756364 (sapanisertib weekly), 2022
  NCT02756364
RCTla/mBC - HR-positive - 2nd line (L2)sapinasertib plus fulvestrantfulvestrantPostmenopausal women with histologic confirmation of ER-positive and HER2-negative metastatic or advanced BC48 / 46NA
inconclusive
    no statistically significant result